Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login


The Cancer Letter Inc.
PO Box 9905
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Nov 3, 2015
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Telotristat Etiprate Demonstrates Clinical Benefit in Phase III Carcinoid Syndrome Study


Telotristat etiprate showed clinical benefit in treating carcinoid syndrome in cancer patients not adequately controlled by long-acting somatostatin analog therapy, the current standard of care, according to data from the phase III TELESTAR study.

The study was presented at the European Cancer Congress in Vienna, Austria.

Telotristat etiprate, developed by Lexicon Pharmaceuticals Inc., met the study’s primary endpoint with clinically meaningful reductions in bowel movement frequency in patients whose condition was not adequately controlled by SSA therapy. Carcinoid syndrome is characterized by frequent and debilitating diarrhea, as well as by facial flushing, abdominal pain, and heart valve damage.

To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.